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Background: Polycystic ovarian syndrome (PCOS) is characterized by the presence of multiple follicular cysts, giving
rise to infertility due to anovulation. This syndrome affects about 10% of women, worldwide. The exact molecular
mechanism leading to PCOS remains obscure. RhoGTPase has been associated with oogenesis, but its role in PCOS
remains unexplored. Therefore, we attempted to elucidate the Vav-Rac1 signaling in PCOS mice model.
Methods: We generated a PCOS mice model by injecting dehydroepiandrosterone (DHEA) for a period of 20 days.
The expression levels of Rac1, pRac1, Vav, pVav and Caveolin1 were analyzed by employing immuno-blotting and
densitometry. The association between Vav and Rac1 proteins were studied by immuno-precipitation. Furthermore,
we analyzed the activity of Rac1 and levels of inhibin B and 17β-estradiol in ovary using biochemical assays.
Results: The presence of multiple follicular cysts in ovary were confirmed by histology. The activity of Rac1
(GTP bound state) was significantly reduced in the PCOS ovary. Similarly, the expression levels of Rac1 and its
phosphorylated form (pRac1) were decreased in PCOS in comparison to the sham ovary. The expression
level and activity (phosphorylated form) of guanine nucleotide exchanger of Rac1, Vav, was moderately
down-regulated. We observed comparatively increased expressions of Caveolin1, 17β-estradiol, and inhibin B in the
polycystic ovary.
Conclusion: We conclude that hyperandrogenization (PCOS) by DHEA diminishes ovarian Rac1 and Vav expression
and activity along with an increase in expression of Caveolin1. This is accompanied by an increase in the intra-ovarian
level of '17 β-estradiol and inhibin B.
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The pool of primordial follicles in the ovary supply
eggs for the entire reproductive life in mammals. To
maintain fertility for the whole reproductive period, the
primordial follicles are reserved in a quiescent state for
regulated successive ovulation [1-3]. Primordial follicles
are recruited from the reserve of dormant follicles into the
pool of growing follicles through their activation process
during which they undergo a series of developments [3].* Correspondence: rajesh_jha@cdri.res.in
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unless otherwise stated.Polycystic ovarian syndrome (PCOS) is characterized by
anovulation and in the presence of multiple small
cysts typically arranged in the periphery of one or
both ovaries. PCOS can affect 5–10% of women dur-
ing their reproductive age and contributes to this eti-
ology in about 10% of the infertile women [4-6]. This
disorder is considered to be a manifestation of the
disturbance in the endocrine system, which causes
secondary disorders contributing to female infertility
[7]. The most commonly seen endocrine disturbance
is hyperandrogenism accompanied by chronic oligo or
anovulation [8]. The hypothalamic-pituitary synchrony is
disrupted that increases pulsatile secretion of gonadotropin,
disturbs oocyte-granulosa cell interaction, enhancesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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production and that leads to insulin resistance [9]. As a re-
sult, metabolic syndrome (MS) is seen in about 46% of the
PCOS cases [10].
However, the intra-ovarian pathophysiology of PCOS
is not yet explicit at cellular and molecular levels. The
available data till date is insufficient to precisely delin-
eate the intra-ovarian pathway that contributes to the
development of this disorder. Therefore, we need further
investigations to pinpoint the correct mechanism leading
to the development of this disorder. The G-protein family
member, Ras, has already been shown to participate in the
pathophysiology of PCOS [11]. Another member of Rho
family protein, Rac, is involved in gonad formation [12]
and acts downstream to integrin signaling [13]. Its ex-
pression/activity is controlled by estrogen [14]. Rho
guanine dissociation inhibitor (RhoGDI) antagonizes Rac1
and keeps it in the inactive state [15,16]. The Rho assists in
actin dynamics through cofilin regulation by Luteinizing
hormone signaling [17] in the granulosa cells [18]. Further-
more, Rac modulates cell cycle [19], which is activated by
guanine exchange factor Vav [20,21]. Further, it is reported
that Rac gets phosphorylated in the process of its activation
[22]. Similarly, Vav also gets phosphorylated before it exe-
cutes Rac activation [23,24]. Looking at the role of Rac/Vav
signaling in ovarian physiology, we designed the present
study to analyze expression and activity of Rac1 and Vav
proteins in the ovary of a mice model of PCOS.
Materials and methods
Reagents
Dehydroisoandrosterone 3′-sulphate (cat no. D5297),
hematoxylin (cat no. H3136), anti-beta-actin (cat no.
A2668) and goat anti-Mouse IgG (γ-chain specific)-HRP
(cat no. A3673) were purchased from Sigma Aldrich Inc.,
St Louis, MO, USA. Immobilon-P PVDF membrane
(0.45 μm), ECL reagent kits (cat no. WBKLS0500), Protein-
A-Agarose suspension (cat no. IP02) and goat anti-rabbit-
HRP IgG (cat no.621140380011730) were procured from
Merck-Millipore, Cedex, France. Other primary antibodies
against phospho-Vav (Y174) (cat no. ab47282), phospho-
Rac1/Cdc42 (S71) (cat no. ab5482) and Rac1 (cat no.
ab33186) were purchased from Abcam, Cambridge, MA,
USA. Anti-Vav (cat no. sc132) and anti-Caveolin1 (cat no.
sc894) were purchased from Santa Cruz Biotechnology,
CA, USA. Non-fat milk (cat no.170-6404) and precision
plus protein standard marker (cat no. 161-0374) were ob-
tained from Bio-Rad Lab., Inc., Hercules, CA., USA. Protein
assay kit (cat no. 23225) was procured from Thermo-
Scientific, Rockford, USA. The G-LISA Rac1 activation
assay Biochem Kit (cat no. BK128) was purchased from
Cytoskeleton, Denver, CO, USA. Inhibin B Enzyme Im-
munoassay kit (cat no. EIA-INB-1) was purchased from
RayBiotech, Inc., Norcross, GA, USA. 17 β-estradiol assaykit (cat no. ADI-900-008) was obtained from Enzo Life Sci-
ence, Inc., Farmingdale New York, USA.
PCOS experimental animal model
The murine model of PCOS was developed by
administering Mus musculus (strain C57/BL6) with
dehydroisoandrosterone (DHEA). PCOS was induced
in 22 days old mice (12 gm) by injecting DHEA
(6 mg/100gm body weight; dissolved in 0.01 ml 95%
ethanol, which was further diluted with corn oil)
subcutaneously for 20 consecutive days as described
previously [25-28]. The model is characterized by
higher levels of serum testosterone, androstenedione
and 5-alpha-dihydrotestosterone similar to that seen in
PCOS patients. Previous studies have established that the
DHEA-PCOS murine model represents some of the salient
features of human PCOS, such as hyperandrogenism,
abnormal maturation of ovarian follicles and anovulation
[26,27,29-31]. We administered corn oil along with 95%
ethanol in the control (sham) group. Animal usage and the
protocols were duly approved by the Institutional Animal
Ethics Committee of the CDRI, Lucknow, India. The
animals were housed in a temperature-controlled facility
(25 ± 1°C) with required illumination (12 h light and 12 h
dark). Free access to food and water were provided to the
animals. At the end of the experiments, animals were
sacrificed by cervical dislocation followed by excision of
ovaries, which were snap frozen at −80°C until further use.
Each treatment/control group consisted of six animals.
Ovarian tissue histology and staining
To evaluate the histological alteration in the ovary, DHEA
treated and sham/control ovaries were dissected and
allowed to fix overnight at 4°C in 4% paraformaldehyde
(PFA)-phosphate buffered saline (PBS). On subsequent
day, tissue samples were kept in the tissue cassette and
dehydrated using acetone (two times for 30 min each),
acetone + benzene (1:1, 30 min) and cleared in benzene
(two times for 30 min each). Subsequently, the tissues
were removed and embedded in paraffin wax (Fisher
Scientific, Rockford, USA) for 4 h at 65°C. This was
followed by preparation of tissue paraffin moulds.
Embedded ovarian tissues were sectioned (5 μm) using
microtome (Leica Biosystem, Germany) and mounted on
poly-L-lysine (Sigma-Aldrich, MO, USA) coated glass
slides. Sections were deparaffinized with two changes of
xylene (10 min each) and rehydrated with subsequent
changes of absolute alcohol (two times, five min each),
95% (two min) and 70% alcohol (two min). Sections were
briefly washed (three times) and stained with hematoxylin
solution for eight min. After staining, sections were again
washed and kept for blue color development in 1.5%
ammonium hydroxide (30% stock) for 30 sec. The
tissue section mounted slides were washed in distilled
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and counterstained with 0.5% eosin for 30 sec. This
was followed by dehydration through 95% and absolute
alcohol two times for five min each. Finally, the slides
were cleared in xylene two times for five min each and
mounted with DPX mountant. The tissue sections were
imaged through Inverted Phase Contrast Microscope
(TS100-F, Nikon, Japan) using 5.2 megapixels digital
camera (DS-Fi2-U3, Nikon, Japan).
Ovarian protein extract preparation
After excision, the ovaries were processed for total
(cytosol + plasma membrane) protein extract preparation.
The ovarian tissue was minced and homogenized in a
buffer containing 100 mM KCl, 3 mM NaCl, 3.5 mM
MgCl2, 10 mM PIPES, 1.5 mM EGTA, 1 mM PMSF,
50 g/ml, phosphatase, and protease inhibitors (pH-7.4)
[32]. The tissue homogenate was centrifuged at 200 × g
for 10 min at 4°C to pellet-out unbroken cells and tissue
debris. Later, the mitochondrial fraction was removed
by centrifuging the preparation at 12,000 × g. The
concentration of protein was estimated using Pierce
BCA protein assay kit as per the manufacturer’s
instructions. Suitable concentration (20μg) of protein
extract was prepared for down-stream purposes.
Rac1 activity assay
The activity of Rac1 (GTP bound form) was assayed in the
ovarian protein extract using G-LISA Rac1 activation
assay Biochem Kit, as per the manufacturer’s instructions
and that is already validated [33]. Briefly, a total of 50 μg
protein extract was added to each corresponding well
pre-coated with Rac-GTP-binding protein. This was
incubated at 4°C for 30 min followed by successive
incubation with 50 μl of anti-Rac1 for 45 min. Later,
secondary antibody conjugated with HRP (50 μl) was
incubated for 45 minutes. Subsequently, 50 μl of HRP
detection reagent was added to each well, followed by
incubation for another 20 min. The reaction was
stopped by the addition of 50 μl of HRP stop solution
and the absorbance was recorded at 490 nm.
Inhibin B assay
The level of inhibin B was determined in the ovarian pro-
tein extract using RayBio Inhibin B Enzyme Immunoassay
kit as per the manufacturer’s instructions. We added
100 μl of inhibin B antibody in each well of micro-plate,
which was pre-coated with anti-rabbit antibody. The plate
was incubated overnight at 4°C with gentle shaking.
This was followed by the addition of 100 μl of protein
sample to each well and incubation overnight at 4°C.
HRP-Streptavidin was added followed by incubation at
room temperature for 45 min. Subsequently, 100 μl
of 5’-tetramethylbenzimide (TMB) was added as HRPdetection reagent and incubated at room temperature in
dark for 30 min. The reaction was terminated by adding
50 μl stop solution and absorbance was recorded at
450 nm.
17 β-estradiol hormone estimation
The assay was performed as per instructions provided by
the manufacturer. A total of 40 μg (100 μl) ovarian
protein (n = 4; sample pooled from 10 animals to form 4
replicate in each group) was used for this assay. The
standard of 17 β-estradiol was prepared by the addition of
100 μl standards (30,000 pg/ml, 7,500 pg/ml, 1,875 pg/ml,
468.8 pg/ml, 117.2 pg/ml and 29.3 pg/ml) and assay
buffer3 (50 μl) into respective standard wells, whereas the
standard diluent (100 μl) was added to well B0 (maximum
binding well). The NSB (negative control) received stand-
ard diluents (100 μl), assay buffer3 (50 μl) and conju-
gate (phosphatase conjugated with 17β-estradiol)
(50 μl). Blank was prepared by adding only substrate
(200 μl) and stop solution (50 μl). Next, we added
50 μl of conjugate in all the wells except blank. Antibody
against 17β-estradiol (50 μl) was added in wells B0,
standard, and samples only followed by incubation of plate
at room-temperature (RT) for 2 h. The unbound/excess
content was decanted and micro-plate was washed thrice
with 400 μl of wash buffer by gentle tapping on
paper towel. Thereafter, a substrate (p-nitrophenyl
phosphate; 200 μl) was added in each well followed
by incubation at RT for 45 min. Finally, a stop solution
(trisodium phosphate; 50 μl) was added to each well
and micro-plate was read at 405 nm using micro-plate
reader (SPECTRO star Nano, BMG LABTECH, GmbH,
Germany). The graph was plotted with absorbance versus
standards (17β-estradiol; pg/ml) after subtraction of NSB
values. The concentration of 17β-estradiol was calculated
based on the standard curve.
Co-immuno-precipitation assay
The ovarian protein lysate (100 μg, sham group) from
each replicate was immuno-precipitated by incubation
with anti-Vav overnight at 4°C. To collect the immune
complexes, Protein-A-Agarose (20 μl) was added and
the lysate-bead mixture was incubated at 4°C under
rotary agitation for 4 h. It was followed by centrifugation
at 10,000 × g for 10 min at 4°C and washing three times
with PBS. Protein was eluted with Laemmli buffer and
boiled for 5 min. The supernatant was subjected to 12%
SDS-PAGE and immuno-blotted with anti-Rac1 according
to a previously described method [32].
SDS-PAGE and Western blotting
Protein sample (20 μg) was denatured by boiling in
Laemmli buffer [34] for 5 min at 95°C and applied on a
10-12% SDS-PAGE. The proteins resolved on the gel were
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buffer (20% methanol, vol/vol; 0.19 M glycine; 0.025 M
Tris-Base, pH = 8.3) [35]. The membrane was blocked
with 5% non-fat milk/goat serum and incubated overnight
at 4°C with antibodies against Rac1 (1:1000 dilution),
pRac1 (1:1000 dilution), Vav (1:250 dilution), pVav (1:1000
dilution), Caveolin1 (1:1000 dilution) and beta-actin
(1:6000 dilution). Thereafter, the membranes were
incubated for one h with goat anti-rabbit IgG or goat
anti-mouse IgG conjugated with Horseradish Peroxidase
in a paraffin boat. Phosphate buffered saline (10 mM,
pH 7.4 containing 0.1% Tween-20, PBS-T) was used
throughout the procedure. Later, the membranes were
exposed to ECL reagents to visualize the protein bands and
imaged through Chemi-Imager (ImageQuant LAS4000,
Buckinghamshire, UK). Immuno-positive bands were
analyzed by densitometry using Total Lab Quant 1D
software (Nonlinear Dynamics Ltd., UK). The beta-actin
blot values were used to normalize the blots value of Rac1,
pRac1, Caveolin1, Vav and pVav.
Statistical analysis
All the experiments were performed in three replicates
using six animals in each group. Ovarian tissue samplesFigure 1 Morphological comparison of DHEA treated mouse ovary w
luteum and secondary follicle (A and C), DHEA treated PCOS ovary showin
granulosa cells (B and D). Corpus-luteum was completely absent in polycywere pooled from two animals to form one replicates to in-
crease the yield of protein extract. Protein band intensities
were averaged and the standard error of the mean (SE) was
calculated. The data were subjected to one-way ANOVA
using Microsoft Excel 2007. P values less than 0.05 were
considered significant for statistical inference.
Results
Characterization of PCOS by histological analysis
To demonstrate the effect of DHEA, ovaries were
sectioned and stained with hematoxylin/eosin. Ovarian
sections of control (sham) group showed the presence of
follicles at different stages of maturation (Figure 1).
Atretic, graffian and healthy follicles were clearly visible
along with corpora lutea (Figure 1A). The presence of
healthy oocytes in the follicles was seen (Figure 1C). In
contrast, DHEA treated ovary exhibited a bit distorted
morphology (Figure 1B). The numbers of antral and
pre-natal follicles were increased with arrangement
typically that of the polycystic ovary; however, the
granulosa cells appeared to be degenerated (Figure 1D).
The size of the polycystic ovary was increased, perhaps
due to an increase in the number of follicles. Oocytes and
corpora-lutea were not seen in the polycystic ovary.ith its control. Sham/vehicle ovary showing (4x magnification) corpus
g (10× magnification) follicular cyst (FC) along with degenerate
stic ovary.
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The level of inhibin B correlates with the number of
follicles recruited to undergo maturation [36]. Earlier
studies have reported high concentrations of serum
inhibin B in polycystic ovaries [37-39]. Herein, we
performed assay of inhibin B in ovarian tissue protein
extract to validate the pathophysiology of PCOS in
our animal model. We observed a significant increase
(p < 0.015) in level of inhibin B in the polycystic
ovaries in comparison to sham (control) ovaries. Our
result showed ~61% elevation in the level of inhibin B
(Figure 2A).
Elevated level of 17 β-estradiol in the PCOS ovary
Serum level of 17β-estradiol (E2) indicates the development
of dominant follicles [36]. Therefore, we analyzed intra-
ovarian level of 17β-estradiol in the PCOS and control
groups. We observed about three folds elevation in the level
of estradiol in PCOS ovary in comparison to the control
ovary (p < 0.03) (Figure 2B).Figure 2 Level of inhibin B and 17β-estradiol in sham and
DHEA treated mouse ovary. The intra-ovarian level of inhibin B (A)
and 17-β-estradiol (B) were assessed post treatment of DHEA/sham
in mouse.Down regulation of activity and expression of Rac1 in
PCOS ovary
In order to decipher the possible involvement of Rac1
signaling in PCOS, we detected the expression level of
Rac1 and phosphorylated-Rac1 (S71) (pRac1) in the ovar-
ian tissue protein extract prepared from the experimental
model of PCOS. As shown in Figure 3A, compared with
the sham/vehicle treated ovaries, the activity level of
Rac1 was significantly decreased in the PCOS ovary.
Similarly, the expression level of Rac1 protein was
significantly down-regulated in DHEA treated/PCOS
ovary (Figure 3B and C).
Further, to determine whether the activity of Rac1 in
terms of its phosphorylation was affected in the DHEA
treated (polycystic) ovary, the phosphorylation level of
Rac1 was analyzed employing immuno-blotting. Treatment
of ovary with DHEA resulted in down-regulation of pRac1
(Figure 3D and E). Thus, this domain of information
suggests that DHEA/polycystic ovary may adversely affect
the activity of Rac1.
Association of Vav activity in PCOS ovary
Rac1 is activated by Vav, which gets phosphorylated at
tyrosine (Y) 174 [40]. To evaluate whether DHEA can
also modulate of intra-ovarian activity of Rac1, we
further evaluated the activity and expression level of Vav
in the ovary after DHEA treatment (polycystic ovary).
The activity of Vav in terms of its phosphorylation was
analyzed through phosphorylation assay/Western blots
(Figure 4). We found reduced expression level of total
Vav in the hyper-androgenized ovary, but the difference
in comparison to control was not statistically significant
(Figure 4A and B). Similarly, the intensity of anti-pVav
(Y174) positive band was found to be lower in PCOS
in comparison to the control (sham) group (p > 0.05)
(Figure 4C and D).
Vav can interact with Rac1 in ovary
It is well known that Vav displays guanidine exchange
factor activity for Rho GTPases. We performed co-
immuno-precipitation analysis to confirm the Rac1 asso-
ciation with Vav in the sham ovary. The Vav presence in
the Vav antibody IP was confirmed by its immuno-
blotting (Figure 5A). As shown in Figure 5B, the immuno-
precipitated protein samples by Vav antibody from the
ovary of sham administered displayed immuno-positive
band of Rac1, which is an indication that Rac1 interacts
with Vav in the ovary.
Caveolin1 is up-regulated in PCOS ovary
Caveolin1 is known to be an important scaffolding
domain containing caveolae protein, which is involved in
the regulation of several signaling cascades [41]. Since,
Caveolin1 is linked to Rac1 degradation pathway, we
Figure 3 Determination of expression and activity of Rac1 in DHEA induced PCOS ovary. Relative activity of Rac1 was analyzed in the
DHEA (PCOS) and sham treated ovary (A). Expression level analysis of Rac1 was determined by immuno-blotting and densitometry in the ovary
of PCOS and sham (B and C). The activity Rac1was assayed by analysis of its phosphorylated form (D and E).
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ovarian samples. We observed a significantly increased
level of Caveolin1 in PCOS ovary in comparison to the
control (sham) group (Figure 6A and B).
Discussion
Intra-ovarian signaling stimulates some of the primordial
follicles to grow out of a cohort. The quiescent follicles
remain in the inactive stage due to inhibitory mechanism
operational either within the follicles or by the signals
from the ovary [3]. During the post-natal development
in mice, a large number of oocytes/follicles are de-
pleted in comparison to the growing population of
follicles [42,43]. This phenomenon is similar in the
humans as well [3] and depletion of the pool of primodial
follicles compromises female fertility. The condition of fol-
licle insufficiency to ovulate is not understood precisely.
Previous studies have demonstrated the association of
Ras and Rho signaling in the process of ovarian follicle
development [43-48]. Rac1 is a member of the Ras family,making it a good candidate for investigation of its role
in the regulation of follicular maturation.
The presence of multiple cysts in the ovaries are consid-
ered as a key diagnostic trait of PCOS [49-51], which was
precisely mimicked in our PCOS mice model. This pro-
vided us with a platform for further biochemical and ex-
pression analysis. Our histological findings in PCOS ovary
correlated well with the earlier reports showing increased
ovarian size, absence of ovum and corpus-luteum in the
ovaries of DHEA treated mice [52]. A relation be-
tween decrease in ovarian volume and the number of
follicles with age of women with PCOS has been shown
[53]. Increased level of inhibin B and 17β-estradiol in the
PCOS group demonstrated elevation in the number of re-
cruited dormant follicles in comparison to the control
ovary [36]. Collectively, this confirmed a phenotype of
polycystic ovary in our model system.
The estradiol negatively affects Rac1 activation [14],
and in turn Rac1 regulates inhibin B [54]; however,
this is not known in the ovarian tissue. Rac is a member
Figure 4 Vav and pVav expression analysis in the PCOS and sham ovary. Phosphorylated-Vav (pVav) was studied in the PCOS (DHEA
treated) ovary (A and B) using Western blotting. Expression level of total Vav and pVav were analyzed using densitometry (C and D).
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member of this G-protein family, Ras, has already
been implicated in the pathophysiology of ovary [11].
A previous study has suggested involvement of Rac1in
gonad formation [12], but its association with follicular
maturation and function has not been shown. Our results
suggested that expression of Rac1, pRac1 and its activity
were significantly reduced in the hyperandrogenized ovary
with DHEA (polycystic ovary). Activity of Rac1 was also
lowered as compared to sham. It has been reported
that higher production of estrogen in vascular smooth
muscle cells causes down-regulation of Rac1 [14]. We
observed a similar combination of elevated level of
intra-ovarian 17β-estradiol and down-regulation of Rac1
on polycystic ovary. Further to confirm the involvement of
Rac1, we studied the expression level of total Vav along
with its phosphorylated form, which is a known activatorof Rac1 [24]. As expected, we observed a reduction in
total Vav and its phosphorylated form. The association
between Rac1-Vav was further confirmed by immuno-
precipitation (IP), which showed Rac1 presence in the
immuno-precipitates prepared using anti-Vav from
sham treated group. Collectively, all the above results
suggest that elevated 17β-estradiol levels might have
down-regulated the activity/expression of Rac1 and
Vav favoring the development of PCOS phenotype.
Several studies have also shown the interaction of
Rac1 with caveolae protein, Caveolin1. Caveolin1 is
known to control Rac1 protein levels by regulating
ubiquitylation and degradation of activated Rac1 in an
adhesion-dependent fashion [55]. The absence of Caveo-
lin1 has been reported to increase the proliferation and
anchorage-independent growth by a Rac-dependent,
Erk-independent mechanism [56]. Since, there is no
Figure 5 Analysis of Rac1 and Vav interaction in the ovary. Lysate from PCOS ovary was processed for Vav immuno-precipitation followed by
immuno-blotting with Rac1 antibody (A); presence of Rac1 in the Vav IP was confirmed by its immuno-blotting (B).
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sue, particularly in PCOS, we analyzed the expression of
Caveolin1. A higher level of caveolin1 in PCOS ovary
might have signaled a decrease in Rac1 and Vav levels that
favors the development of PCOS phenotype. However,
this is purely a speculation and further evidence is re-
quired to conclude the exact role of Caveolin1 in patho-
physiology of PCOS. Rac1 and Caveolin1 are known to
associate during cell proliferation signaling [56]; however,
Caveolin1 antagonizing function for Rac1 activity in PCOS
pathophysiology needs further validation. Herein, our
study can infer that Caveolin1 is dysregulated in the PCOS
ovary.On the basis of our observations, we propose that
increased androgens levels result in enhanced conver-
sion of estradiol that initiates a series of events leading
to the condition of PCOS. It is perhaps increased 17β-
estradiol level that results in down regulation of Rac1
and Vav, ultimately, resulting in suspension of follicu-
lar development. This leads to arrest of follicular
development, and promotes the to accumulation of im-
mature follicles typical to PCOS ovaries. Elevated level of
inhibin B is an indicator of repeated recruitment of folli-
cles in the developmental process that is suspended before
follicular maturation. How increased 17β-estradiol levels
act on Rac/Vav needs to be studied further.
Figure 6 Evaluation of expression of Caveolin1 in the DHEA and sham treated ovary. Immuno-blotting of Caveolin1 was performed in
PCOS and sham ovary group in comparison to the control group (A); Densitometric analysis of Cav1 in PCOS and control group (B).
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The results of this study demonstrate for the first time
diminished activity of Rac1 and Vav in hyperandrogen-
ized mouse ovaries. Our findings might provide some
explanation through small G-protein in the pathogenesis
of follicular hyperplasia in PCOS. Altogether, these
observations suggest a contribution of elevated estradiol
and inhibin B levels due to the DHEA in pathophysiology
of PCOS.
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